Skip to main content
. Author manuscript; available in PMC: 2017 Jan 3.
Published in final edited form as: Nat Rev Clin Oncol. 2012 Sep 11;9(11):643–653. doi: 10.1038/nrclinonc.2012.156

Table 3.

Predicting response rates for therapies based on pathway signatures

Histology n Incidence of activated PI3K
pathway gene signature (%)
Predicted response rate
to PI3K and mTOR
pathway inhibitors (%)
Absent Present
DLBCL 73 38 62 30–36
FL 184 54 46 50–56
HL 130 52 48 53
MCL 15 73 27 32–67
PTCL 50 44 56 63

Abbreviations: DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin lymphoma; MCL, mantle-cell lymphoma; PTCL, peripheral T-cell lymphoma.